The depletion of B-cells using anti-CD20 monoclonal antibodies resulted in significantly diminished pro-inflammatory responses of CD4+ and CD8+ T-cells as well as myeloid cells, and provided evidence of the use of these agents as highly effective therapies both in relapsing and progressive MS. The gene discussed is CD8A; the disease is myeloid sarcoma.